Search

Biogen Inc

Lezárt

SzektorEgészségügy

207.14 0.44

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

203.98

Maximum

207.9

Fő mutatók

By Trading Economics

Bevétel

-639M

-320M

Értékesítés

258M

2.7B

P/E

Szektor átlag

35.911

68.51

Egy részvényre jutó nyereség

3.6

Profit margin

-11.678

Munkavállalók

7,500

EBITDA

-475M

78M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+13.09% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. okt. 29.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-31M

30B

Előző nyitás

206.7

Előző zárás

207.14

Hangulat hírek alapján

By Acuity

49%

51%

147 / 340 Rangsor szerint Healthcare

Biogen Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 7. 23:16 UTC

Social Media

Biogen Inc completed the acquisition of RayThera, valued at up to $1 billion, but shares are lower in after-market trading.

2026. aug. 6. 23:11 UTC

News

Biogen Inc. has completed its acquisition of RayThera Inc., enhancing its immunology portfolio. Shares are trading lower in after-market hours following a recent decline.

2026. aug. 5. 19:26 UTC

News

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Despite strong results, shares are trading lower amid broader market declines.

2026. aug. 4. 20:02 UTC

News

Mizuho raised its price target on Biogen Inc. to $241, contributing to the stock's upward movement during Tuesday's session.

2026. aug. 3. 23:06 UTC

Biogen Inc. shares are trading higher in after-market hours, supported by stronger-than-expected manufacturing data and positive broader market sentiment.

2026. júl. 31. 21:01 UTC

News

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Shares are higher in after-market trading following the positive results and raised EPS guidance.

2026. júl. 30. 19:39 UTC

Biogen Inc shares are lower in Thursday's session, reaching a low of approximately -2.86% earlier. No specific news was identified to explain the decline.

2026. júl. 29. 22:02 UTC

Biogen Inc shares are higher in after-market hours, maintaining a steady upward trajectory since Wednesday's close and staying above the 20-day moving average.

2026. júl. 28. 22:01 UTC

Biogen Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. The stock remains above its 20-day moving average.

2026. júl. 27. 18:56 UTC

Biogen Inc. shares are lower today amid routine trading fluctuations. Broader market declines are influenced by falling oil prices ahead of the Federal Reserve meeting.

2026. júl. 24. 18:26 UTC

Biogen Inc. shares are higher today, continuing an upward trend since Thursday. The stock's movement appears independent of recent oil price volatility.

2026. júl. 22. 22:01 UTC

Biogen Inc shares are trading higher in after-market hours, reflecting an increase since Wednesday's close amid broader market volatility and rising crude oil prices.

2026. júl. 21. 19:46 UTC

News

BIIB trading higher after Guggenheim raised price target to $280.

2026. júl. 20. 22:06 UTC

Biogen Inc. shares rose slightly in after-market hours, despite broader market pressure from a decline in the Conference Board's leading economic index.

2026. júl. 17. 20:02 UTC

Biogen Inc's shares are lower today, continuing a downward trend since Thursday. The broader market reflects a general decline amid notable sell-offs in technology stocks.

2026. júl. 16. 19:02 UTC

News

Biogen partners with Synapticure to launch a virtual ataxia care program. Shares are higher today, reflecting positive sentiment since Wednesday's close.

2026. júl. 15. 23:36 UTC

Biogen Inc. shares declined in after-market trading, reflecting ongoing weakness amid broader market caution related to geopolitical tensions involving the U.S. and Iran.

2026. júl. 14. 23:41 UTC

Event
News

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

2026. júl. 13. 23:06 UTC

Social Media
News

Biogen received FDA approval for LEQEMBI IQLIK, a subcutaneous Alzheimer's treatment, boosting shares modestly higher in after-market trading.

2026. júl. 10. 21:01 UTC

Biogen Inc shares declined in after-market trading, reversing an initial uptick and nearing the lower end of their one-month trading range. No specific news was identified.

2026. júl. 9. 23:46 UTC

Biogen Inc shares are trading lower in after-market hours, continuing a trend of five consecutive daily declines without any specific news to explain the movement.

2026. júl. 8. 23:56 UTC

Biogen Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing lower, with no specific news identified for the decline.

2026. júl. 7. 23:31 UTC

Biogen Inc shares are higher in after-market trading following Tuesday's close, amid broader market volatility but stable performance above its 20-day moving average.

2026. júl. 6. 23:56 UTC

Biogen Inc. shares are higher in after-market trading, reflecting a slight upward movement since Monday's close and settling near the upper end of their one-month range.

2026. júl. 2. 22:16 UTC

Biogen Inc shares are lower in after-market hours, reflecting a decline since Thursday's close amid mixed market sentiment and a weaker jobs report.

2026. júl. 1. 20:07 UTC

Event

Biogen Inc. shares are lower as broader market sell-offs raise volatility. Barclays notes vulnerabilities in U.S. equity markets affecting investor sentiment.

2026. jún. 30. 19:56 UTC

Event

Biogen will present new Alzheimer’s data at the AAIC 2026, including findings from the Phase 2 CELIA study and LEQEMBI analyses. Shares are higher today.

2026. jún. 29. 23:02 UTC

Event

Biogen will present new Alzheimer’s data at AAIC 2026, but shares are lower in after-market hours amid broader market volatility and geopolitical tensions.

2026. jún. 26. 19:51 UTC

News

Biogen Inc pauses investment in most legacy Apellis programs, aligning with current objectives. Shares are higher today, reflecting positive investor response to the restructuring.

2026. jún. 25. 22:36 UTC

Biogen Inc's shares are higher in after-market trading, reflecting a notable upward trajectory since Thursday's close amid mixed broader market results.

Társak összehasonlítása

Árváltozás

Biogen Inc Előrejelzés

Célár

By TipRanks

13.09% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 233.29 USD  13.09%

Magas 300 USD

Alacsony 157 USD

28 Wall Street elemző 12 hónapos célárain alapulva a(z)Biogen Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

28 ratings

18

Vétel

9

Tartás

1

Eladás

Hangulat

By Acuity

147 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat